IPN Ipsen SA

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 46 - 2025

IPSEN - Achats effectués dans les conditions de l'Article 5 du Règlement MAR - Semaine 46 - 2025

Présentation agrégée par jour et par marché



Déclaration des transactions sur actions propres réalisées du 10 Novembre au 14 Novembre 2025
       
Nom de l'émetteurCode identifiant de l'émetteur (code LEI)Jour de la transactionCode identifiant de l'instrument financierVolume total journalier (en nombre de titres)Prix pondéré moyen journalier d'acquisitionCode identifiant marché
IPSEN549300M6SGDPB4Z94P1110/11/2025FR0010259150 300 127,30000AQEU
IPSEN549300M6SGDPB4Z94P1110/11/2025FR0010259150 1 000 127,60000CEUX
IPSEN549300M6SGDPB4Z94P1110/11/2025FR0010259150 300 127,38767TQEX
IPSEN549300M6SGDPB4Z94P1110/11/2025FR0010259150 2 307 126,70893XPAR
IPSEN549300M6SGDPB4Z94P1111/11/2025FR0010259150 500 128,90000CEUX
IPSEN549300M6SGDPB4Z94P1111/11/2025FR0010259150 2 330 128,80854XPAR
IPSEN549300M6SGDPB4Z94P1112/11/2025FR0010259150 600 130,05000AQEU
IPSEN549300M6SGDPB4Z94P1112/11/2025FR0010259150 1 500 130,56620CEUX
IPSEN549300M6SGDPB4Z94P1112/11/2025FR0010259150 600 129,80000TQEX
IPSEN549300M6SGDPB4Z94P1112/11/2025FR0010259150 1 600 129,93200XPAR
IPSEN549300M6SGDPB4Z94P1113/11/2025FR0010259150 673 130,48113AQEU
IPSEN549300M6SGDPB4Z94P1113/11/2025FR0010259150 2 000 130,36540CEUX
IPSEN549300M6SGDPB4Z94P1113/11/2025FR0010259150 300 129,70000TQEX
IPSEN549300M6SGDPB4Z94P1113/11/2025FR0010259150 1 527 130,11657XPAR
IPSEN549300M6SGDPB4Z94P1114/11/2025FR0010259150 300 130,36667AQEU
IPSEN549300M6SGDPB4Z94P1114/11/2025FR0010259150 1 300 130,57115CEUX
IPSEN549300M6SGDPB4Z94P1114/11/2025FR0010259150 100 130,55000TQEX
IPSEN549300M6SGDPB4Z94P1114/11/2025FR0010259150 2 500 130,55904XPAR
    19737129,45209 

Pièce jointe



EN
19/11/2025

Underlying

IPNIpsen SA

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Ipsen SA

 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone...

Ipsen update on Phase II FALKON trial in patients with ultra-rare bone disease, fibrodysplasia ossificans progressiva (FOP) PARIS, FRANCE, 19 December 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) today announced that the pivotal Phase II FALKON trial did not meet its primary endpoint of reducing new heterotopic ossification (HO) in adults and children living with fibrodysplasia ossificans progressiva (FOP) vs. placebo, as a result the study will be closed. The investigational medicinal product (fidrisertib) was generally well tolerated, with no safety concerns in the trial. “These results are ...

December 19, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen fait le point sur l'essai de Phase II FALKON chez les patients a...

Ipsen fait le point sur l'essai de Phase II FALKON chez les patients atteints d’une maladie osseuse ultra-rare, la fibrodysplasie ossifiante progressive (FOP) PARIS, FRANCE – 19 décembre 2025 – Ipsen (Euronext : IPN ; ADR : IPSEY) annonce aujourd'hui que l'essai pivotal de Phase II FALKON n'a pas atteint son critère principal, à savoir la réduction du volume de formation anormale de nouvelle matière osseuse (ossification hétérotopique ou OH) chez l’adulte et l’enfant atteints de fibrodysplasie ossifiante progressive (FOP), par rapport au placebo, en conséquence, l'étude sera clôturée. Le mé...

December 19, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi...

Ipsen finalise l'acquisition d'ImCheck Therapeutics, élargissant ainsi son portefeuille de produits oncologiques PARIS, FRANCE, 15 DECEMBRE 2025 - Ipsen (Euronext: IPN; ADR: IPSEY) annonce aujourd’hui avoir finalisé l'acquisition d'ImCheck Therapeutics, une société privée française de biotechnologie pionnière dans le domaine des thérapies d’immuno-oncologie de nouvelle génération. A propos d’Ipsen Nous sommes un groupe biopharmaceutique mondial focalisé sur la mise au point de médicaments innovants pour les patients dans trois domaines thérapeutiques : l’Oncologie, les Maladies Rare...

December 15, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncolog...

Ipsen completes acquisition of ImCheck Therapeutics, expanding oncology pipeline PARIS, FRANCE, 15 December 2025 – Ipsen (Euronext: IPN; ADR: IPSEY) today announced it has completed the acquisition of ImCheck Therapeutics, a private French biotechnology company pioneering next-generation immuno-oncology therapies. About Ipsen We are a global biopharmaceutical company with a focus on bringing transformative medicines to patients in three therapeutic areas: Oncology, Rare Disease and Neuroscience. Our pipeline is fueled by internal and external innovation and supported by nearly 100 year...

December 15, 2025 1 EN
 PRESS RELEASE
Free
IPN IPSEN SA

IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025

IPSEN - Buy-back programme - Art 5 of MAR - Week 49- 2025 Aggregated presentation by day and by marketStatement of transactions in own shares from December 1st to December 05th 2025       Name of the issueIdentity code of the issuer (Legal Entity Identifier) Day of the transactionIdentity code of the financial instrument Total daily volume (in number of shares)Daily weighted average purchase price of the sharesMarket (MIC Code) IPSEN549300M6SGDPB4Z94P1101/12/2025FR0010259150200124,05000AQEUIPSEN549300M6SGDPB4Z94P1101/12/2025FR0010259150831123,81540CEUXIPSEN549300M6SGDPB4Z94P1101/12/2025FR0...

December 9, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch